<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1138">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146336</url>
  </required_header>
  <id_info>
    <org_study_id>O06</org_study_id>
    <nct_id>NCT05146336</nct_id>
  </id_info>
  <brief_title>CytOSorb TreatMent Of Critically Ill PatientS Registry</brief_title>
  <acronym>COSMOS</acronym>
  <official_title>CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytoSorbents, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytoSorbents, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry intended to provide a data repository and reporting infrastructure for the&#xD;
      surveillance of CytoSorb device use in real-world critical care settings, and to serve as an&#xD;
      objective, comprehensive, and scientifically-based resource to measure and improve the&#xD;
      quality of patient care&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">June 2031</completion_date>
  <primary_completion_date type="Anticipated">March 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>Through ICU discharge or date of death, whichever comes first [on average 7 days]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Through hospital discharge or date of death, whichever comes first [on average 14 days]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Critical Illness</condition>
  <condition>Septic Shock</condition>
  <condition>Vasogenic Shock</condition>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <condition>Liver Failure</condition>
  <condition>Trauma</condition>
  <condition>Rhabdomyolysis</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Vasoplegic Syndrome</condition>
  <condition>Cardiogenic Shock</condition>
  <condition>Pancreatitis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CytoSorb</intervention_name>
    <description>Sorbent hemoperfusion system</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Critically ill patients receiving CytoSorb therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CytoSorb utilization in the setting of critical illness&#xD;
&#xD;
          -  Informed consent for prospective registry participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of the CytoSorb device for antithrombotic removal&#xD;
&#xD;
          -  Use of the CytoSorb device during cardiac surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catalin Mindrescu, MD</last_name>
    <phone>7329976228</phone>
    <email>CMindrescu@cytosorbents.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Rhabdomyolysis</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Vasoplegia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

